Edwards Lifesciences announced today that it received CE mark for its Evoque tricuspid valve replacement system. Irvine, California-based Edwards says the regulatory nod makes it the first transcatheter valve replacement therapy to receive approval to treat tricuspid regurgitation (TR). Evoque features a nitinol self-expanding frame and an intra-annular sealing skirt. It makes the device’s tissue […]
Edwards Lifesciences
Report: Patent practices triggered EU antitrust probe into Edwards
Reuters reports that European officials probed Edwards Lifesciences over potential antitrust activity because of patent practices. The outlet cites a person familiar with the matter regarding the European Commission’s scrutiny of the U.S.-based medtech company. Last month, the European Commission said it conducted a surprise inspection at an undisclosed medtech company. It listed that company […]
State of the industry — Execs ‘more bullish than ever’ on medtech
Ernst & Young’s 2023 Pulse of the Industry medical technology report may not have been overly positive, but medtech executives certainly are. The EY report highlighted sluggish revenues and post-COVID-19 corrections leading to a growth decline. In fact, it was the lowest growth in medtech since 2015. Roughly half of medtech stock price gains realized […]
Report: Edwards is cooperating with EU amid antitrust scrutiny
According to reports, Edwards Lifesciences is the company under scrutiny in Europe for potential antitrust activity. Reuters reports that the company is working with EU antitrust regulators on the matter. The European Commission said last week that it conducted a surprise inspection at an undisclosed medtech company. It listed that company as active in the cardiovascular […]
Edwards software may reduce duration, severity of hypotension, study says
Edwards Lifesciences today announced study results that support the use of its Acumen HPI software. Results from the EU-HYPROTECT registry indicate that using Acumen HPI may help reduce the duration and severity of intraoperative hypotension in patients having non-cardiac surgery. In June, Edwards shared results from the registry that also demonstrated the software’s success. The […]
TAVR sales were up 9% for Edwards in Street-beating Q2
Edwards Lifesciences shares fell after hours today despite second-quarter results that beat the consensus forecast. Shares of EW dipped 6.3% to $85.85 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 0.6%. The Irvine, California-based company posted profits […]
Study says Edwards software could help reduce hypotension
Edwards Lifesciences today announced results from a registry demonstrating the effect of software on reducing hypotension. The EU-HYPROTECT registry evaluated patients having non-cardiac surgery. Results indicated that the Edwards Acumen HPI software may help reduce the duration and severity of intraoperative hypotension. Edwards said the European multicenter prospective observational registry included, in its final analysis, […]
Hologic CEO MacMillan to chair Illumina’s board
Illumina (NASDAQ: ILMN) announced today that its board has elected Hologic CEO Stephen MacMillan to fill a new seat and become its non-executive chair. Edwards Lifesciences CFO Scott Ullem will fill a second new seat — bringing the number of board seats to 11 at the San Diego–based DNA sequencing and array-based tech developer. The […]
Medtronic stock down as growth projections underwhelm
Medtronic today reported fourth-quarter results that beat the consensus forecast on Wall Street amid accelerating revenue growth. The world’s largest medical device company also announced an acquisition, planning to pay roughly $738 million for South Korea–based EOFlow and its EOFlow insulin delivery patch that a user can control using their smartphone. However, its forecast for […]
Study backs Edwards aortic valve with Resilia tissue
Edwards Lifesciences (NYSE:EW) today announced new data from a clinical trial evaluating bioprosthetic aortic valves with its Resilia tissue. Data from the COMMENCE aortic trial demonstrated low rates of structural valve deterioration (SVD) in the bioprosthetic valves. It represents the longest clinical follow-up for Edwards’ valve with Resliia tissue at a mean of 7.7 years. […]
Edwards beats The Street in Q1, raises 2023 guidance to up to 12% sales growth
Edwards Lifesciences shares dipped despite first-quarter results that topped the consensus forecast. Shares of EW were down slightly to $86.72 apiece by the close of trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up slightly. The Irvine, California–based medical device maker yesterday […]